Despite recent advances in the therapeutic control of immune function and viral infection, current therapies are often challenging to develop, expensive to deploy and readily select for resistance-conferring mutants. Shaped by the host-virus immunological ‘arms race’ and tempered in the forge of deep time, the biodiversity of our world is increasingly being harnessed for new biotechnologies and therapeutics. Simultaneously, a shift towards host-oriented antiviral therapies is currently underway. In this Clinical & Translational Immunology Special Feature, I outline a strategic vision integrating these themes to create a new generation of effective, economical and robust antiviral treatments and immunotherapies. Durable international cooperation over the coming decades is necessary to achieve this, so here I invite leading international experts to discuss frontiers in host-oriented therapies, methods for modulating immune gene expression and applications of recent genome sequencing technologies, including an emerging research field.
- information economy paradox
- post-transcriptional regulation
- drug repurposing